Opinion

Video

Expert Insights into Navigating Cardiovascular Risks with BTKi Therapy

Author(s):

Catherine C. Coombs, MDBrian T. Hill, MD, PhD

A panel of expert oncologists explore the influence of hypertension risk and other cardiovascular AEs in guiding treatment selection with BTKis, sharing insights from ASH 2023.

Related Videos
David L. Porter, MD
Suneel Kamath, MD
Suneel Kamath, MD
Mazyar Shadman, MD, MPH
BTK Inhibitors in CLL : Second Generation Drugs and Beyond
David L. Porter, MD
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic
Video 14 - "Key Takeaways in HER2-Mutated NSCLC"
Video 13 - "Treatment Considerations in HER2-Mutated NSCLC"
Kathleen A. Dorritie, MD
Related Content
Moritz Fürstenau, MD, of the University of Cologne
June 13th 2024

Venetoclax Plus Obinutuzumab With or Without Ibrutinib Extends PFS in First-Line CLL

Jubilee Brown, MD, professor, director, Gynecologic Oncology, Atrium Health Levine Cancer Institute
May 13th 2024

Brown Highlights the Rationale for the RAMP-301 Trial in Low-Grade Serous Ovarian Cancer

Sanjal Desai, MD, medical oncologist, Mayo Clinic; assistant professor, medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota
May 28th 2024

Desai Details Efforts Exploring Treatment Strategies in CLL Post–BTK Inhibitor Progression

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Sanjal Desai, MD, assistant professor, medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota
May 24th 2024

Genetic Information and Patient Factors Influence BTK Inhibitor Sequencing in Frontline CLL and Beyond

James Ignatz-Hoover, MD, PhD
May 24th 2024

Weighing the Benefits and Limitations of CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma